Home
overview
Without doubt the Human Genome Project has taken several giant leaps into the twenty-first century. Today, with the advancement of genome research, we confront important issues such as proteomics and bioinformatics. There is a growing recognition that one of the key ways in which companies are going to obtain maximum return on their investment in genomics is to include strong capabilities in the fields of proteomics, in silico and bioinformatics

Beyond the genome will cover how computational and biological methods will make sense of genomic data (from the human genome project). The major areas to be covered will be Genomics, Proteomics, Bioinformatics and In Silico.

A unique opportunity to learn from leading industry experts including:
Dr Christian Rohlff, Director, Proteome Research Collaborations,Oxford GlycoSciences
Dr Fiona Brew, Field Applications Manager, Europe, Affymetrix
Dr Stefan Henning, Director, Functional Biology, Xerion Pharmaceuticals
Dr Frits Michels, Group Leader, Galapagos Genomics
Dr Joachim Ostermann, Director Target Discovery, Caprion Pharmaceuticals
Dr John Murphy, Vice President & Chief Information Officer, CuraGen

Benefits of attending:
Keep up with the latest developments and innovations in genomics, proteomics and bioinformatics
Learn from leading experts in the field
Discover the latest technologies in genomics
Understand the opportunities and advantages in the post-genomic era
Take advantage of the networking opportunities
Meet key decision-makers

Conference programme

8:30 Registration and Coffee

9:00 Chairman's Opening Remarks

Dr Christian Rohlff

Dr Christian Rohlff, Director, Proteome Research Collaborations, Oxford GlycoSciences

9:10 NEW CHALLENGES IN THE POST-GENOMIC ERA

Dr Fiona Brew

Dr Fiona Brew, Field Applications Manager, Europe, Affymetrix

9:40 DRUG DISCOVERY IN THE POST-GENOMIC ERA

Dr John Overington

Dr John Overington, Vice President, Drug Discovery, Inpharmatica

  • Using protein structure to identify novel drug targets
  • Integrating bioinformatics and chemogenomics
  • Drugability assessment as a key criterion in target prioritisation
  • Linking target, drug and disease indication
  • 10:20 IN SILICO DRUG DISCOVERY

    Dr Jonathan Swinton

    Dr Jonathan Swinton, Senior Computational Biologist, Proteom

  • The history of drug discovery over the last decade has been an increasing expense and failing productivity
  • This problem drives the huge interest in proteomics and the application of technologies, which can provide a fast way of generating data on the biological function of a protein, and hence its importance as a drug target
  • Moving from data to knowledge is a new frontier for drug discovery
  • Genomics projects have taught us one major lesson: too much information can be a problem in drug discovery
  • Instead of using ‘random’ or ‘combinatorial’ approaches which are expensive and resource intensive, we need to develop smart approaches which can utilise artificial intelligence concepts to enable us to complete some of the discovery studies in silico
  • Proteom has applied advance data mining and artificial intelligence approaches to identify rules and principles that characterise protein-protein interactions

    Knowledge of the 3D structure of a given protein is not an essential starting point for this analysis

    In silico approaches are a new frontier in drug discovery

  • 11:00 Morning Coffee

    11:20 ULTRA HIGH-THROUGHPUT DNA ANALYSIS AND THE RACE FOR PREDICTIVE MEDICINE

    Dr Mark Benjamin

    Dr Mark Benjamin, President, US Operations & Vice President, Global Business Development, Manteia Predictive Medicine

    12:00 INDUSTRIAL PROTEOMICS

    Dr Christian Rohlff

    Dr Christian Rohlff, Director, Proteome Research Collaborations, Oxford GlycoSciences

  • It is still not certain which regions of the genome code is for proteins
  • The number of discrete protein-coding genes is far fewer than the number of different proteins
  • Proteomics is now addressing “post genomic” issues
  • Discovery and development of new medicines is critically dependent on the discovery of protein mechanisms involved in human diseases
  • Integrating proteomics throughout the R & D process is likely to impact positively the discovery of clinically relevant proteins
  • 12:40 Networking Lunch

    14:00 ORGANELLE PROTEOMICS

    Dr Joachim Ostermann

    Dr Joachim Ostermann, Director Target Discovery, Caprion Pharmaceuticals

  • Comparative analysis of different proteomic approaches
  • Benefits and costs savings derived from individual applications
  • Description of proprietary technology developed to comprehensively identify all proteins in biological samples and to determine their relative expression level between samples
  • Examples of use of CellCarta organelle proteomic approach including data in target discovery in oncology and novel protein function/mechanism of action understanding in infectious disease
  • 14:40 A PLATFORM TECHNOLOGY FOR SYSTEMATIC, AUTOMATED HIGH THROUGHPUT PROTEIN EXPRESSION

    Dr Linda Cammish

    Dr Linda Cammish, Director, Business Development, NextGen Sciences

    15:20 Afternoon Tea

    15:40 STRUCTURAL PROTEOMICS

    Dr Ray Owens

    Dr Ray Owens, Project Manager, Oxford Protein Production Facility

  • UK initiatives in structural proteomics
  • Developing a high-throughput pipeline for protein production and crystallisation
  • Target selection and data management
  • Future perspectives
  • 16:20 X-STREAM™

    Dr Stefan Henning

    Dr Stefan Henning, Director, Functional Biology, Xerion Pharmaceuticals

  • Proteins are the drug targets of choice
  • Chromophore-assisted laser inactivation (CALI) is an efficient protein knockout technology
  • Combination of CALI, scFv phage display and mass spectrometry results in a technology platform for the systematic identification and functional validation of novel drug targets
  • Screening of human antibody libraries for inhibitory antibodies against validated target protein
  • Application example in cancer metastasis
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Re-registration and Coffee

    9:00 Chairman's Opening Remarks

    Dr John Murphy

    Dr John Murphy, Vice President & Chief Information Officer, CuraGen

    9:10 LOOKING FORWARD IN PROTEOMICS

    Dr Thomas Neumann

    Dr Thomas Neumann, Managing Director, Xzillion

  • High-throughput proteomics and generating valuable data
  • New technology developments: PST™ (Protein Sequence Tags), data about the process and its opportunities
  • The advantage of the Membrane PST™ approach for the identification of membrane proteins undiscovered by the conventional approach
  • Using Tandem Mass Tagging for accurate quantitative analysis
  • Examples on application and the outcome
  • Scaling bioinformatic solutions to handle the enormous data
  • 9:40 BIOINFORMATICS IN THE PHARMA INDUSTRY

    Dr Dominic Clark

    Dr Dominic Clark, Consultant, Scientific Generics

  • The global bioinformatics industry
  • Commercial paradigms
  • Industry trends and evolution
  • Future dynamics
  • 10:20 COMBINATORIAL AND INTEGRATIVE BIOINFORMATICS

    Matthias  Fellenberg

    Matthias Fellenberg, Project Manager, Scientific Bioinformatics, Biomax Informatics

  • Generating biologically relevant results using integrative bioinformatics methods
  • Employing independent data types to support a functional and metabolic analysis
  • Combining genomics, proteomics, and metabolomics data
  • Mining protein-protein interactions on a large scale
  • Realising flexible analysis workflows to support systems biology
  • 11:00 Morning Coffee

    11:20 NEGOTIATING THE IP MINEFIELD

    Zoe Butler

    Zoe Butler, Senior Associate, Bioinformatics Group, Bristows

  • What IP rights are being granted in Europe and the US
  • Maximising the capture of IP rights
  • Can you leverage your databases to reach through to royalties based on drug sales?
  • Freedom to operate strategies and royalty stacking
  • 12:00 INFORMATICS SOLUTIONS FOR TARGET DISCOVERY, VALIDATION, PRIORITISATION AND MANAGEMENT

    Dr Martin Leach

    Dr Martin Leach, Directory, Discovery Bioinformatics, CuraGen

  • How to organise a virtual scientific software workbench
  • How to rapidly develop LIMS to support the drug development process
  • Presentation of a case study on use of an informatics platform for target discovery through validation
  • Informatics for clinical site and network management
  • Automation of converting data to knowledge in technical reports for validation and registration
  • 12:40 Networking Lunch

    14:00 HIGH-THROUGHPUT DISCOVERY OF DRUG TARGETS

    Dr Frits Michiels

    Dr Frits Michiels, Group Leader, Galapagos Genomics

  • Interfering small RNA collections against drugable gene classes in arrayed adenoviral format
  • Full length cDNAs of drugable gene classes in arrayed adenoviral format
  • High-throughput screening with disease relevant cellular assays
  • Primary human cells in cellular screens
  • Programmes for the identification and validation of targets in osteoporosis, rheumatoid arthritis, Alzheimer’s disease, psoriasis and allergy
  • 14:40 CORPORATE STRATEGY & ALLIANCES

    Dr David Huckle

    Dr David Huckle, Chief Executive, Adams Business Associates

  • Macromarket dynamics to establish strategic vision
  • Corporate micromarket dynamics as basis for alliances
  • Considerations for a successful alliance
  • Defining and achieving winning relationships
  • Growth or survival as basis for possible partners
  • Implementation and management
  • 15:20 Chairman's Closing Remarks followed by Afternoon Tea
    Close of Conference

    +

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.